Caroline Seymour

Lyndsey Runaas, MD, discusses the newfound outlook for patients with FLT3- and IDH1/2-mutant acute myeloid leukemia given recent regulatory approvals and trial data.

A vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer, induced antibody and T-cell responses toward the specified target and demonstrated an acceptable safety profile in this patient population

Laura Kruper, MD, MS, discusses outstanding questions within the context of the current management of the axilla.

Martin Dietrich, MD, PhD, discusses ways of offsetting neratinib-associated diarrhea for patients with early-stage HER2-positive breast cancer at high risk of recurrence in need of extended adjuvant therapy.

Yuan Yuan, MD, PhD, discusses how treating physicians are optimizing novel agents for patients with metastatic triple-negative breast cancer.

The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.

Eric S. Winer, MD, highlights the targeted therapies that have made the biggest clinical impact for patients with acute myeloid leukemia.

Although TKIs have significantly improved life expectancy for patients with chronic myeloid leukemia, investigators are actively examining ways to safely discontinue treatment without sacrificing benefit.

Christine N. Duncan, MD, discusses the current components of CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

Kartik Konduri, MD, discusses the use of combination therapies and newer agents in patients with targetable driver mutations.

Clinical outcomes were found to be consistent among transplant-eligible patients with mantle cell lymphoma, irrespective of the chemoimmunotherapy induction regimen that was administered.

David P. Mason, MD, discusses the available treatment approaches for patients with locally advanced non–small cell lung cancer.

Matthew S. Davids, MD, MMSc, discusses recent shifts in the chronic lymphocytic leukemia paradigm with the use of novel therapies and the need to increase personalized treatment with these agents.

Giada Bianchi, MD, discusses the scope of frontline therapy and subsequent maintenance strategies among patients with transplant eligible and ineligible newly diagnosed multiple myeloma.

Mariana Chavez Mac Gregor, MD, MSc, discussex recent shifts in the treatment of patients with metastatic triple-negative breast cancer.

Although biological criteria carry prognostic value in mantle cell lymphoma, initial observation based solely on clinical criteria was found to be an effective management strategy that did not compromise patient outcomes.

Cindy Osborne, MD, highlights the many advances that have been made in the treatment paradigms of locally advanced and metastatic HER2-positive breast cancer.

Joyce A. O’Shaughnessy, MD, discusses the clinical implications of the TEXT and SOFT trials for women with premenopausal HR-positive, HER2-negative breast cancer, as well as unanswered questions that remain with adjuvant endocrine therapy.

Mariana Chavez Mac Gregor, MD, MSc, discusses the optimal applications of these assays in patients with early-stage, HR-positive/HER2-negative breast cancer and shed light on the overall outlook of personalized medicine in this setting.

Jonathan Mizrahi, MD, discusses recent pivotal data in colorectal cancer and its impact on personalized care in the treatment paradigm.

Benjamin Leon Musher, MD, reflects on the progress that has been made in hepatocellular carcinoma and highlights promising combinations that are emerging in the space.

Prasad S. Adusumilli, MD, sheds light on the preliminary phase I data from a trial of CAR T-cell therapy in malignant pleural disease from mesothelioma.

Although there are several maintenance strategies to consider for patients with advanced ovarian cancer, the decision of which approach to pursue largely depends on the molecular makeup of an individual patient’s tumor.

Chrisann Kyi, MD, discusses the utility of PARP inhibitors in the primary treatment and maintenance settings for patients with recurrent ovarian cancer and the next steps that lie ahead.

Jason A. Konner, MD, sheds light on the current treatment landscape for patients with platinum-sensitive and platinum-resistant/recurrent ovarian cancer

Britta Weigelt, PhD, discusses germline and somatic mutations in ovarian cancer that confer potential implications on treatment decisions, as well as those that carry an added cancer risk.

Dmitriy Zamarin, MD, PhD, discusses ongoing research regarding immunotherapy and synergistic strategies also under investigation in advanced ovarian cancer.

Jordan D. Berlin, MD, sheds light on current and future directions in the field of locally advanced pancreatic cancer.

Paul Sabbatini, MD, clarifies where the field stands regarding the use of bevacizumab, intraperitoneal therapy, and a 3-week dosing schedule of chemotherapy versus a weekly dose-dense regimen in the frontline setting of newly diagnosed ovarian cancer.

J. Stuart Salmon, MD, highlights first-, second-, and third-line treatment options for patients with gastric and gastroesophageal cancer following recent clinical trial findings and regulatory approvals.